Rhabdomyoblastic differentiation in gastrointestinal stromal tumors after tyrosine kinase inhibitor therapy

被引：0
|
作者：
Liegl, B.
Hornick, J. L.
Antonescu, C. R.
Corless, C. L.
Letcher, C. D. M.
机构：
[1] Brigham & Womens Hosp, Boston, MA 02115 USA
[2] Mem Sloan Kettering Canc Ctr, New York, NY 10021 USA
[3] Oregon Hlth & Sci Univ, Portland, OR 97201 USA
来源：
LABORATORY INVESTIGATION | 2008年 / 88卷
关键词：
D O I：
暂无
中图分类号：
R-3 [医学研究方法]; R3 [基础医学];
学科分类号：
1001 ;
摘要：
50
引用
收藏
页码：14A / 14A
页数：1
相关论文
共 50 条
  • [31] Neoadjuvant tyrosine kinase inhibitor therapy for patients with gastrointestinal stromal tumor: A propensity-matched analysis
    Wong, Liam H.
    Sutton, Thomas L.
    Sheppard, Brett C.
    Corless, Christopher L.
    Heinrich, Michael C.
    Mayo, Skye C.
    AMERICAN JOURNAL OF SURGERY, 2022, 224 (01): : 624 - 628
  • [32] A phase 2 study of ponatinib in patients (pts) with advanced gastrointestinal stromal tumors (GIST) after failure of tyrosine kinase inhibitor (TKI) therapy: Initial report.
    Heinrich, Michael C.
    vonMehren, Margaret
    Demetri, George D.
    Fletcher, Jonathan A.
    Sun, Jichao
    Hodgson, J. Graeme
    Rivera, Victor M.
    Turner, Christopher D.
    George, Suzanne
    JOURNAL OF CLINICAL ONCOLOGY, 2014, 32 (15)
  • [33] Results of tyrosine-kinase inhibitor therapy followed by surgical resection for metastatic gastrointestinal stromal tumor
    DeMatteo, Ronald P.
    Maki, Robert G.
    Singer, Samuel
    Gonen, Mithat
    Brennan, Murray F.
    Antonescu, Cristina R.
    ANNALS OF SURGERY, 2007, 245 (03) : 347 - 352
  • [34] Tumor lysis syndrome after treatment of a gastrointestinal stromal tumor with the oral tyrosine kinase inhibitor sunitinib
    Saylor, Philip J.
    Reid, Tony R.
    JOURNAL OF CLINICAL ONCOLOGY, 2007, 25 (23) : 3544 - 3546
  • [35] A novel tyrosine kinase switch is a mechanism of imatinib resistance in gastrointestinal stromal tumors
    D Mahadevan
    L Cooke
    C Riley
    R Swart
    B Simons
    K Della Croce
    L Wisner
    M Iorio
    K Shakalya
    H Garewal
    R Nagle
    D Bearss
    Oncogene, 2007, 26 : 3909 - 3919
  • [36] A novel tyrosine kinase switch is a mechanism of imatinib resistance in gastrointestinal stromal tumors
    Mahadevan, D.
    Cooke, L.
    Riley, C.
    Swart, R.
    Simons, B.
    Della Croce, K.
    Wisner, L.
    Iorio, M.
    Shakalya, K.
    Garewal, H.
    Nagle, R.
    Bearss, D.
    ONCOGENE, 2007, 26 (27) : 3909 - 3919
  • [37] Intracellular concentration of the tyrosine kinase inhibitor imatinib in gastrointestinal stromal tumor cells
    Berglund, Erik
    Ubhayasekera, Sarojini Jayantha Kumari A.
    Karlsson, Fredrik
    Akcakaya, Pinar
    Aluthgedara, Warunika
    Ahlen, Jan
    Frobom, Robin
    Nilsson, Inga-Lena
    Lui, Weng-Onn
    Larsson, Catharina
    Zedenius, Jan
    Bergquist, Jonas
    Branstrom, Robert
    ANTI-CANCER DRUGS, 2014, 25 (04) : 415 - 422
  • [38] Phase I Study of Rapid Alternation of Sunitinib and Regorafenib for the Treatment of Tyrosine Kinase Inhibitor Refractory Gastrointestinal Stromal Tumors
    Serrano, Cesar
    Leal, Alessandro
    Kuang, Yanan
    Morgan, Jeffrey A.
    Barysauskas, Constance M.
    Phallen, Jillian
    Triplett, Olivia
    Marino-Enriquez, Adrian
    Wagner, Andrew J.
    Demetri, George D.
    Velculescu, Victor E.
    Paweletz, Cloud P.
    Fletcher, Jonathan A.
    George, Suzanne
    CLINICAL CANCER RESEARCH, 2019, 25 (24) : 7287 - 7293
  • [39] Prediction of morbidity following cytoreductive surgery for metastatic gastrointestinal stromal tumour in patients on tyrosine kinase inhibitor therapy
    Fairweather, M.
    Cavnar, M. J.
    Li, G. Z.
    Bertagnolli, M. M.
    DeMatteo, R. P.
    Raut, C. P.
    BRITISH JOURNAL OF SURGERY, 2018, 105 (06) : 743 - 750
  • [40] Longitudinal analysis of the impact of the introduction of tyrosine kinase inhibitor therapy on overall survival of patients with gastrointestinal stromal tumors treated at the West German Cancer Center
    Falkenhorst, J.
    Treckmann, J. W.
    Nguyen, B. -P
    Podleska, L. -E
    Reis, A. -C
    Virchow, I
    Schuler, M.
    Bauer, S.
    Oncology Research and Treatment, 2015, 38 : 167 - 167
12345